Homocysteine, Folate, and Cardiovascular Disease | Nature Research Intelligence
Learn how Nature Research Intelligence gives you complete, forward-looking and trustworthy research insights to guide your research strategy.
Related Articles
Canada named most positive leader on world stage
According to a study by Ipsos, Canada remains the top country expected to have a positive influence on world affairs.
Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial
Nature Medicine – As presented at the 2025 ASCO GI Cancers Symposium: in the phase 3 BREAKWATER trial, patients with previously untreated BRAF V600E metastatic…
It’s Not Just Olive Oil ― Science Says Other Parts Of The Plant Are Good For Our Health Too
What can’t that one tree do…
Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial
Nature Medicine – As presented at the 2025 ASCO GI Cancers Symposium: in the phase 3 BREAKWATER trial, patients with previously untreated BRAF V600E metastatic…
Bioprosthetic vs Mechanical Aortic Valve Replacement in Patients 40-75 Years:
BackgroundThe choice of bioprosthetic or mechanical surgical aortic valve replacement (AVR) should balance individual valve durability with the potential liabilities of oral anticoagulation.Objecti…
Everolimus Plus Lanreotide Extends PFS in Patients With Aggressive Gastroenteropancreatic Neuroendocrine Tumors
The phase 3 STARTER-NET trial found that everolimus plus lanreotide more than doubles progression-free survival among patients with aggressive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) versus everolimus…
Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial
Nature Medicine – As presented at the 2025 ASCO GI Cancers Symposium: in the phase 3 BREAKWATER trial, patients with previously untreated BRAF V600E metastatic…
First-in-Class CD123-Directed Therapy Shows Early Activity in MDS, CMML | Blood Cancers Today
In early study presented at the 66th American Society of Hematology Annual Meeting & Exposition, tagraxofusp demonstrated signs of clinical activity in patients with MDS…
Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial
Nature Medicine – As presented at the 2025 ASCO GI Cancers Symposium: in the phase 3 BREAKWATER trial, patients with previously untreated BRAF V600E metastatic…
ASCO Gastrointestinal Cancers Symposium – Research Summaries for
Visit this page during the meeting to find patient-friendly summaries of highlighted research.